INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIA

Author(s)

Omelyanovskiy V1, Avxentyeva M2, Sura M1, Savilova AG3, Khachatryan G1
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, Moscow, Russian Federation, 2Center of Expertize and Quality Control of Medical Care, Ministry of Health of the Russian Federation, Moscow, Russia, Moscow, Russian Federation, 3Moscow Institute of Physics and Technology (State University), Dolgoprudny, Russian Federation

OBJECTIVES: The aim of this study was to estimate incremental cost-effectiveness ratio (ICER) for the antineoplastic drugs approved and rejected for the vital and essential drugs list (VEDL) in 2017 in Russia. Presently pharmacoeconomic analysis is required for the drug to be included into VEDL, but the use of ICER is not mandatory. METHODS: We used a simplified methodology of calculating ICER for the drugs proposed for the inclusion into VEDL in 2017 in order to compare the values for the approved and rejected medicines. Data on efficacy was derived from the randomized clinical trials (RCT). RCT was considered eligible for deriving data if it showed statistically significant difference in overall or progression-free-survival between the new drug vs the drug already included into Russian VEDL. ICER was calculated by the formula where the numerator was the difference in costs between compared drugs, and the denominator was the difference in life years saved or life years without tumor progression. Progression-free survival was used as criteria of efficacy only if data on overall survival does not exist. RESULTS: ICER for the antineoplastic drugs included into the VEDL with a proved benefit in overall survival rate varies approximately from 8,000 USD to 264,000 USD per life-year saved. Approved drugs with a proved benefit in progression-free survival have ICER from 28,000 USD to 839,000 USD per life year without tumor progression. The only rejected drug with a proved benefit in overall survival has ICER of 73,000 USD. The rejected drugs with a proved benefit in progression-free survival have ICER that varies from 31,000 USD to 124,000 USD. CONCLUSIONS: The ICER for drugs approved for the inclusion into Russian VEDL 2017 varies significantly and often exceeds the same indicator for the rejected drugs.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PCN286

Topic

Health Policy & Regulatory

Topic Subcategory

Reimbursement & Access Policy

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×